Posted by Michael Wonder on 19 Jul 2022
Incyte announces U.S. FDA approval of Opzelura (ruxolitinib) cream for the treatment of vitiligo
18 July 2022 - Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation.
Incyte today announced that the U.S. FDA has approved Opzelura (ruxolitinib) cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older.
